Flordeluna Z Mesina*, Jomell C Julian, Jesus Relos, Rosalio Torres, Maureen Via M Comia, June Marie P Ongkingco and Jimmy R. Lafavilla
Introduction: The Novel Coronavirus (COVID-19) has gripped our country with strain as well as effecting our health system. Currently, there are no standard guidelines in its treatment but the possible benefits of convalescent plasma in limiting complications and treating COVID-19 disease is being looked upon.
Objective: This study aims to determine the effectiveness and safety of using convalescent plasma in improving clinical course of hospitalized patients diagnosed with COVID-19.
Methods: This is a quasi-experimental (prospective analytical) multi-center study of 65 patients who received convalescent plasma therapy (CPT).
Results: Median age of patients who were given CPT was 60 years, were predominantly male (68%), and presented with severe COVID-19 pneumonia. Median hemoglobin presented was 138 g/dl, median WBC count was 7.54 × 10 9 /L and median platelet count was 239,500 × 109/L. All inflammatory markers were increased, and both PaO2 and PFR were deranged. Statistically significant decrease in hemoglobin and LDH, and increase in platelet were seen after intervention of CPT. There was statistically significant longer length of stay among CPT recipients, and there was also noted less mortality in BAT group although this is insignificant.
Conclusion: Convalescent plasma may have shown no significant impact in the recovery rate and outcome compared to patients who have not received convalescent plasma therapy, but its administration was proven to be safe among all patients regardless of the level of severity and clinical profile.
HTML PDFShare this article
Journal of Blood & Lymph received 443 citations as per Google Scholar report
